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Fully continuous manufacturing of therapeutic proteins is an emerging trend in the biopharmaceutical industry. 
Integration of the upstream and downstream processes and conversion to continuous manufacturing leads to 
increased productivities, decreased equipment size, improved product quality, and overall reduced production 
costs. An integrated continuous bioprocess (ICB) from the early stages of process development can accelerate 
the transfer of a new drug candidate to commercial manufacturing. The process presented in this work is a 
proof-of-concept of an end-to-end monoclonal antibody (mAb) production platform at small scale. It was 
implemented by a 200 mL ATF perfusion bioreactor, integrated with a single lab-scale chromatography system, 
performing all purification steps for the mAb from the cell culture harvest in a continuous way. The downstream 
process consisted of a periodic twin-column capture with protein A resin, followed by a virus inactivation step, a 
cation exchange step in bind-elute mode, and an anion exchange step in flow-through mode. MAbs were 
produced for 17 days in a high cell density perfusion culture of CHO cells and purified continuously with a 
recovery yield of up to 60 % by the following downstream train. A 5-log reduction of host cell protein levels 
revealed that impurities were sufficiently removed. A consistent glycosylation pattern of the purified product was 
ensured by the steady-state operation of the process. With this proof-of-concept, we demonstrated the technical 
feasibility of a fully continuous end-to-end process with a compact design, integrating several unit operations in 
a single chromatography station and using small-size equipment for the upstream and downstream operations. 
The work presented here can become a useful development tool for the future of continuous bioprocesses. 
 
 
 
 
 
